Wuhan Coronavirus Resource Thread

The Strategic Issues & International Relations Forum is a venue to discuss issues pertaining to India's security environment, her strategic outlook on global affairs and as well as the effect of international relations in the Indian Subcontinent. We request members to kindly stay within the mandate of this forum and keep their exchanges of views, on a civilised level, however vehemently any disagreement may be felt. All feedback regarding forum usage may be sent to the moderators using the Feedback Form or by clicking the Report Post Icon in any objectionable post for proper action. Please note that the views expressed by the Members and Moderators on these discussion boards are that of the individuals only and do not reflect the official policy or view of the Bharat-Rakshak.com Website. Copyright Violation is strictly prohibited and may result in revocation of your posting rights - please read the FAQ for full details. Users must also abide by the Forum Guidelines at all times.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Today's official vaccination numbers:

COVID-19 Vaccination Update- Day 117
India’s Cumulative Vaccination Coverage exceeds 17.70 Cr doses

Over 4.1 lakh beneficiaries of age group 18-44 Vaccinated today till 8 pm

More than 17.7 lakh vaccine doses administered today

The cumulative number of COVID-19 vaccine doses administered in the country stands at 17,70,85,371 as per the 8 pm provisional report today.

4,17,321 beneficiaries of the age group 18-44 years received their first dose of COVID vaccine today and cumulatively 34,66,895 across 30 States/UTs since the start of Phase-3 of the vaccination drive.

As on Day-117 of the vaccination drive (12th May, 2021), total 17,72,261 vaccine doses were given. 9,38,933 beneficiaries were vaccinated for 1st dose and 8,33,328 beneficiaries received 2nd dose of vaccine as per the provisional report till 8 P.M. Final reports would be completed for the day by late tonight.
Amber G.
BRF Oldie
Posts: 9263
Joined: 17 Dec 2002 12:31
Location: Ohio, USA

Re: Wuhan Coronavirus Resource Thread

Post by Amber G. »

I also feel that Delhi cut down on testing so that the pandemic rages on. Can it be proven by data?
FWIW: From what I know about 2 Million/day is close to practical upper capacity in India at this time. I think the estimation of these U in SUTRA model is quite good in spite of less testing - Hope ICMR does another sero survey soon for some more input/data/ to update so parameters can be more accurately determined.

In any case testing numbers for today from ( covid19india.org) - Cases: 348,555 vs. 329,491 day before. The increase was smaller than expected -- Tests: 19.83L vs. 18.50L y'day. TPR slightly less than before - Overall good trend.
vijayk
BRF Oldie
Posts: 8760
Joined: 22 Jun 1999 11:31

Re: Wuhan Coronavirus Resource Thread

Post by vijayk »

https://www.indiatvnews.com/news/india/ ... ine-704133
Polio vaccine maker BIBCOL to manufacture 2 crore doses of Covaxin at UP's Bulandshahr plant every month
BIBCOL is a PSU of the government. It was established in 1989 in Bulandshahar. It manufactures oral polio vaccines and other immunisers.

Covaxxim manufacturer Bharat Biotech and BIBCOL have signed an MoU for the production of the vaccine at Bulandshahr plant. The Ministry of Health will provide Rs 30 crore financial aid for the production of Covaxin.

BIBCOL will manufacture Covaxin with its existing spare capacity. The production will begin immediately. The company had earlier informed that it has the capabilities to manufacture Covaxin as per the government directives.

The company can manufacture 6 crore doses of polio vaccine per year with existing facilities. Besides, BIBCOL also makes Zinc Dispersible Tablets and Diarrhea Management Kits.

Notably, the government has roped in other vaccine makers to accelerate the production of vaccines in the fight against Covid-19. Earlier in April, the Centre had granted permission to Haffkine Institute, Mumbai to manufacture Covaxin on the basis of the transfer of technology.

Covaxin is currently being administered to the people in the country along with Covishield. Pune-bases Serum Institute of India is manufacturing Covishield -- the local version of Oxford-AstraZeneca COVID-19 vaccine. Only three vaccines have been approved to be sold in India -- Covaxin, Coveshield and Sputnik V. Sputnik V has been approved to be imported from Russia by Dr Reddy's, but is yet to be widely available in the country.
https://www.indiatvnews.com/news/india/ ... ine-698122
Centre allows Mumbai-based Haffkine Institute to manufacture Covaxin
The Centre has granted permission to Haffkine Institute, Mumbai to manufacture Bharat Biotech's Covid-19 vaccine Covaxin
Amid deteriorating Covid-19 situation in the country, the Centre has granted permission to Haffkine Institute, Mumbai to manufacture Bharat Biotech's Covid-19 vaccine Covaxin. The state-run biomedical research institute will manufacture the drug on the basis of transfer of technology.

"The Department of Science and Technology, Government of India, has granted approval to Haffkine Institute to produce Bharat Biotech's Covaxin vaccine on a transfer of technology basis," the Maharashtra Chief Minister's Office tweeted
Amber G.
BRF Oldie
Posts: 9263
Joined: 17 Dec 2002 12:31
Location: Ohio, USA

Re: Wuhan Coronavirus Resource Thread

Post by Amber G. »

About Masks - As others pointed out, *any* good mask will do - even more important is to wear it properly and snugly when out. (See ICMR or CDC guideline).
(I was particularly familiar and impressed with Swasa story - how a professor and bunch of student hit upon the idea and in few months time India started producing PPE's and masks - still remember photo of Modi wearing it in Ayoudya Ram Temple silyanas).
- In USA there were quite a few low-quality Chinese made KN95 masks and there were many warnings about those. So in USA buy only reputable N95 masks.
- From clinical data - double masking with multilayer good-fitting masks is *very* effective. One less known fact - triboelectric masks - one can easily make them at home - use one layer of silk or such material layer and rubbing it before you put it on can improve it many fold. Even ordinary surgical mask (covered by cloth mask) - rubbed with silk type material - or just rub it with other synthetic material - to produce static electricity - can help. (It is easy so no harm)
IndraD
BRF Oldie
Posts: 9305
Joined: 26 Dec 2008 15:38
Location: भारत का निश्चेत गगन

Re: Wuhan Coronavirus Resource Thread

Post by IndraD »

https://www.ft.com/content/5f742765-61a ... 119cd7d46c
Scientists probe impact of Indian Covid variant on vaccine efficacy
Reports that fully vaccinated people have become infected with Covid-19 in India have concerned some scientists, reigniting the debate over the threat the mutating virus poses to global vaccination campaigns.
Ravi Gupta, professor of clinical microbiology at Cambridge university and one of the leading scientists investigating new strains of Sars-Cov-2, told the Financial Times he had identified “worrying” cases of post-vaccination infection involving at least one of the new variants first identified in India — B.1.617.2
At one care home in Delhi, 33 staff members who had been fully vaccinated with the Oxford/AstraZeneca jab, tested positive for the B. 1.617.2 strain, he said, though none became seriously ill. “We thought everyone would be protected [but] the virus was able to get around the vaccine,” Gupta said.
Gupta’s findings add to the many reports in the Indian media of fully-vaccinated doctors and medical workers testing positive for Covid-19 over the past two months, as the country has been slammed by a ferocious second wave of infections.
The FT has not corroborated individual press reports but the Indian Medical Association said that at least nine of 194 doctors that had died of Covid-19 during the recent outbreak were believed to have been fully vaccinated. The organisation was in the process of verifying more details, including how long after their second shot the doctors had died and which vaccine they had received, Dr Johnrose Austin Jayalal, IMA national president, told the FT.
The question scientists must now answer is whether the so-called “vaccine breakthrough” cases can be explained by the sheer number of people contracting Covid-19 in India and the efficacy of the shots — none of the jabs are 100 per cent effective. Or whether the new strains, as with the variant first identified in South Africa, have evolved to become more resistant to the vaccines.
Chart showing that a surge in B.1.617.2 fuelled India’s second wave. The question is whether the same will happen in countries with high vaccine coverage
Indian virologist Shahid Jameel, a member of the Indian Sars-Cov-2 Consortium on Genomics, said that severe cases of Covid-19 following vaccination remained “very very rare” and that the few incidents were drawing public attention because of the pervasive anxiety in the country, where an average of 388,000 people are testing positive every day.
India had administered 171.1m vaccine doses by May 10, according to FT data — a combination of a locally produced version of the AstraZeneca shot and the Covaxin jab developed by India’s Bharat Biotech. Only 2.6 per cent of the population has been fully vaccinated
“Breakthrough infections are happening because the numbers are so high,” Jameel said. “It is also a fact that a very large majority of breakthrough infections are leading to asymptomatic or mild disease, which can be controlled at home.”
Every country with advanced vaccination programmes has recorded cases of “vaccine breakthrough”. In the US by April 26 the Centers for Disease Control and Prevention had received 9,245 reports of infections in people who had been fully vaccinated, including 835 hospitalisations and 132 deaths.
“Getting infected after vaccination does not tell us anything, it could well be within the expected margin of vaccine efficacy,” said Muge Cevik, a clinician and researcher in virology at Scotland’s University of St Andrews.

Mehul Suthar, assistant professor of paediatrics at Emory University in the US who has been conducting lab analysis of new variants of concern, agreed that there was little severe disease and death occurring in cases of vaccine “breakthrough” but warned of the risks of further mutations.
“The more these variants emerge, the more opportunities they have to mutate, cause infection, and become more transmissible,” he said.
While most scientists remain confident that the current crop of vaccines would protect against severe symptoms and death, there is growing consensus that at least one of the three descendant lineages of the variant initially found in India is partially vaccine-resistant — B.1.617.1.
A paper published this week by Gupta’s lab that has not yet been peer-reviewed, found that B.1.617.1 had “modestly reduced sensitivity” to the BioNTech/Pfizer vaccine. Another paper by Suthar at Emory, found that antibodies were sevenfold less effective at neutralising or blocking the variant in comparison to the original Wuhan strain. That put B.1.617.1 “on a par” with the variant first identified in South Africa, which has been found to reduce the efficacy of some shots, Suthar said. Both the papers stressed, however, that vaccines demonstrated reasonable protection against the disease.
Chart showing that B.1.617.2 is now thought to be dominant in India, and has surpassed other recently imported variants in several countries
The B.1.617.1 variant has a particular mutation, known as E484Q, that is often associated with vaccine escape. That mutation is not present in the B.1.617.2 variant, which has spread from India to roughly 40 countries around the world, but it does have a different mutation called T478K, about which little is known.
“I’d put my money on the T487K mutation [causing breakthrough infections],” Gupta said.
B.1.617.2 is now the second most common variant in the UK, accounting for roughly 12 per cent of virus samples sequenced over the past two weeks, up from 7 per cent one week earlier. In India, where there is less genomic sequencing capability, B.1.617.2 now accounts for roughly 64 per cent of cases, and B.1.617.1 accounts for 12 per cent.
Prevailing scientific opinion is that the B.1.617.2 variant is more transmissible than B.1.617.1 and at least as transmissible as the highly infectious variant, first identified in Kent, UK.
The World Health Organization said this week that preliminary studies suggested that the Indian variant and its sub-lineages spread more quickly and registered the strain as the fourth “variant of global concern”, adding it to those first identified in the UK, Brazil and South Africa.
For Gupta, the Indian variants deliver a firm “warning”.
“If we don’t keep the lid on their spread we may end up with variants that are even better at evading our vaccines,” he said. “It’s key to not underestimate what this virus can do.”
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Vaccine paucity: Maharashtra suspends vaccination for 18-44 age group
Due to acute shortage of COVID-19 vaccine doses, the Maharashtra government on Wednesday decided to suspend the drive to vaccinate those in the age group of 18 to 44 and divert the available stock for the above-45 years category, Health Minister Rajesh Tope said.

The decision was taken during the state cabinet meeting, he told reporters here.

The minister also claimed that the Serum Institute of India (SII) has informed the Maharashtra government that it would be able to provide 1.5 crore Covishield vaccine doses to the state only from May 20.

"There is no sufficient supply of vaccine vials by the Centre for inoculation of above-45 age group people. Hence, the state cabinet decided to divert the stock, purchased for the 18-44 age group, for the above-45 age group," he said.

On Tuesday, Tope had alleged that the Union government was not fulfilling its responsibility to provide adequate number of vaccine doses to states.

"There are some 20 lakh people who have not received their second dose of vaccine. As per the scientific advisory, we can not delay their inoculation further, hence we decided to suspend the inoculation of 18-44 age group," he said.

Some 16 lakh persons are waiting to get second jab of Covishield while the rest are to get a second dose of Covaxin.

To meet this requirement of the above 45 group, around 10 lakh vials meant for the 18-44 age group will be diverted.

Asked about Maharashtra's plans to purchase vaccines from the global market, Tope said, "The vaccines have to be approved by the Union government for their distribution here. The Union government has to first take that decision, then only a state can purchase vaccines from the global market.

Vaccines of Pfizer, Moderna or Johnson and Johnson require lower storage temperatures. Covishield and Covaxin vials can be stored at 2-8 degree Celsius, but other vaccines need temperature below zero, the minister noted.
Najunamar
BRFite
Posts: 431
Joined: 28 Dec 2007 16:40
Location: USA

Re: Wuhan Coronavirus Resource Thread

Post by Najunamar »

I thought only Pfizer and Moderna require ultra-low temperatures - J&J was supposed to be like regular vaccine (2-8 deg C). Even within the 2 Moderna is less stringent as they're claiming it is stable for 30 days at 2-8 deg C (still not sure if FDA has accepted it - recently are making progress according to dork media in US)

https://www.abc10.com/article/news/heal ... 115ddb984a
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Najunamar wrote:I thought only Pfizer and Moderna require ultra-low temperatures - J&J was supposed to be like regular vaccine (2-8 deg C). Even within the 2 Moderna is less stringent as they're claiming it is stable for 30 days at 2-8 deg C (still not sure if FDA has accepted it - recently are making progress according to dork media in US)

https://www.abc10.com/article/news/heal ... 115ddb984a
What makes you think that the Maharashtra Health Minister knows the real facts about storage requirements for different vaccines? :)
Atmavik
BRFite
Posts: 1985
Joined: 24 Aug 2016 04:43

Re: Wuhan Coronavirus Resource Thread

Post by Atmavik »

https://www.opindia.com/2021/05/bombay- ... t-biotech/

Bombay HC orders Maharashtra govt to approve transfer of vaccine plant to Bharat Biotech after forest dept blocked the deal
Amber G.
BRF Oldie
Posts: 9263
Joined: 17 Dec 2002 12:31
Location: Ohio, USA

Re: Wuhan Coronavirus Resource Thread

Post by Amber G. »

I thought only Pfizer and Moderna require ultra-low temperature
.
Roughly speaking -- Cold Storage requirements (from wiki) : Covidsheild, Covaxin, J&J ==> - 2-8 C,
Moderna, Sputnik ==> -18 C (Freezer)
Pfizer ==> -70 C,
vera_k
BRF Oldie
Posts: 3982
Joined: 20 Nov 2006 13:45

Re: Wuhan Coronavirus Resource Thread

Post by vera_k »

Unusual news.

Ethereum co-creator donates $1 billion in crypto for India COVID-19 relief
In more conventional terms, the donation would rank among the philanthropy’s biggest strokes. But little is conventional: The currency, Shiba Inu coin, has been around for less than a year, and is one of a bevy of alternative cryptocurrencies that have exploded in popularity and price in recent months.
srai
BRF Oldie
Posts: 5220
Joined: 23 Oct 2001 11:31

Re: Wuhan Coronavirus Resource Thread

Post by srai »

vijayk wrote:...

They better start now ... Biden's team has no intent to help the world.
Leave the one-liner meaningless politics out. Every country is in a self-serving/saving mode from the pandemic crisis. Things will gradually open up once situations are brought under control in each respective countries. For instance, given the current COVID resurgence crisis in India the world can’t expect GoI to be shipping precious vaccines or O2 plants/storage to other countries.
Atmavik
BRFite
Posts: 1985
Joined: 24 Aug 2016 04:43

Re: Wuhan Coronavirus Resource Thread

Post by Atmavik »

Kakkaji wrote:
Najunamar wrote:I thought only Pfizer and Moderna require ultra-low temperatures - J&J was supposed to be like regular vaccine (2-8 deg C). Even within the 2 Moderna is less stringent as they're claiming it is stable for 30 days at 2-8 deg C (still not sure if FDA has accepted it - recently are making progress according to dork media in US)

https://www.abc10.com/article/news/heal ... 115ddb984a
What makes you think that the Maharashtra Health Minister knows the real facts about storage requirements for different vaccines? :)
the state govts are more interested in playing politics and pushing blame on center. lets see how many are successful in importing these vaccines.
Amber G.
BRF Oldie
Posts: 9263
Joined: 17 Dec 2002 12:31
Location: Ohio, USA

Re: Wuhan Coronavirus Resource Thread

Post by Amber G. »

From this arXiv: Vaccinated individuals can be infected with B.1.617, but without severe disease. The data go some way to explaining the dominance of this variant in a partially immune population, but highlight that vaccination is still protective for the majority of people.
https://www.biorxiv.org/content/10.1101 ... 8.443253v1
>>> First molecular insights into B.1.617 VOC by collaboration of INSACOG and Gupta Lab.
Only moderate antibody resistance but greater syncytium formation. Overall fits higher transmissibility, ?symptoms, but low severity in vaccinated.
chetak
BRF Oldie
Posts: 32224
Joined: 16 May 2008 12:00

Re: Wuhan Coronavirus Resource Thread

Post by chetak »

Image
nandakumar
BRFite
Posts: 1638
Joined: 10 May 2010 13:37

Re: Wuhan Coronavirus Resource Thread

Post by nandakumar »

Amber G. wrote:From this arXiv: Vaccinated individuals can be infected with B.1.617, but without severe disease. The data go some way to explaining the dominance of this variant in a partially immune population, but highlight that vaccination is still protective for the majority of people.
https://www.biorxiv.org/content/10.1101 ... 8.443253v1
>>> First molecular insights into B.1.617 VOC by collaboration of INSACOG and Gupta Lab.
Only moderate antibody resistance but greater syncytium formation. Overall fits higher transmissibility, ?symptoms, but low severity in vaccinated.
I am hearing stories from people in the friends circle and extended family that they contracted Covid infections despite having had two shots of vaccine. Granted that vaccination is not proof against infection the interesting thing is such instances have come predominantly from those who have had Covishield. This was confirmed by a doctor relative of mine. I wonder if there are exhaustive data on infection among vaccinated individuals and the distribution between the two vaccines currently available.
sanjayc
BRFite
Posts: 1091
Joined: 22 Aug 2016 21:40

Re: Wuhan Coronavirus Resource Thread

Post by sanjayc »

<admin> deleted conspiracy theories </admin>
sanjayc
BRFite
Posts: 1091
Joined: 22 Aug 2016 21:40

Re: Wuhan Coronavirus Resource Thread

Post by sanjayc »

nandakumar wrote:
Amber G. wrote:From this arXiv: Vaccinated individuals can be infected with B.1.617, but without severe disease. The data go some way to explaining the dominance of this variant in a partially immune population, but highlight that vaccination is still protective for the majority of people.
https://www.biorxiv.org/content/10.1101 ... 8.443253v1
>>> First molecular insights into B.1.617 VOC by collaboration of INSACOG and Gupta Lab.
Only moderate antibody resistance but greater syncytium formation. Overall fits higher transmissibility, ?symptoms, but low severity in vaccinated.
I am hearing stories from people in the friends circle and extended family that they contracted Covid infections despite having had two shots of vaccine. Granted that vaccination is not proof against infection the interesting thing is such instances have come predominantly from those who have had Covishield. This was confirmed by a doctor relative of mine. I wonder if there are exhaustive data on infection among vaccinated individuals and the distribution between the two vaccines currently available.
For Covaxin, mortality and morbidity due to corona infection after getting the vaccine is negligible. Much lower incidence of side effects too compared to Covishield.
putnanja
BRF Oldie
Posts: 4665
Joined: 26 Mar 2002 12:31
Location: searching for the next al-qaida #3

Re: Wuhan Coronavirus Resource Thread

Post by putnanja »

Also, 90% of the vaccination has been done with covishield, so probability of knowing a covishield vaccinated person getting covid is higher than probability of knowing someone vaccinated with covaxin contracting covid.
Deans
BRF Oldie
Posts: 2500
Joined: 26 Aug 2004 19:13
Location: Moscow

Re: Wuhan Coronavirus Resource Thread

Post by Deans »

The crypto currency guys may be looking for India to legitimize trading - rather than ban it. It may be a combined donation from all players.
Jarita
BRF Oldie
Posts: 2649
Joined: 30 Oct 2009 22:27
Location: Andromeda

Re: Wuhan Coronavirus Resource Thread

Post by Jarita »

Tanaji wrote:One thing I don’t understand: all states are going in for global tenders. We all know what the state of production is with various manufacturers. So why do the states think that they all get anything any faster than what local manufactures can provide after august when the production ramps up? Another point is do they really think they will get it cheaper than Rs 400?

I don’t quite follow the reasoning of this global tender…

Make good money from global tenders. It’s a travesty that a country like India will have to import garbage like Sputnik.
If we think that some of these states are not hoarding and salivating at the opportunity to make something or to please their sponsors, we are kidding.
Some of these vaccine providers could underprice for kill the competition in India.
I hate to say but GOI has to have daily press conferences and full transparency around what is being released to which state. The communication is abysmal. And please not Niti Aayog which will absolutely Tom Tom a global tender.
Tanaji
BRF Oldie
Posts: 4513
Joined: 21 Jun 2000 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Tanaji »

But no vaccine supplier abroad has spare capacity on the scale of what India requires. Not Pfizer, not Moderna and certainly not AZ.

So where will the vaccines come from? It is a matter of 3 months at the most. By end of year, we will be back to exporting.
vijayk
BRF Oldie
Posts: 8760
Joined: 22 Jun 1999 11:31

Re: Wuhan Coronavirus Resource Thread

Post by vijayk »

Image

We have to see if there are any supply constraints for these ....
Suraj
Forum Moderator
Posts: 15043
Joined: 20 Jan 2002 12:31

Re: Wuhan Coronavirus Resource Thread

Post by Suraj »

^^^ very helpful estimate of future availability .
vijayk
BRF Oldie
Posts: 8760
Joined: 22 Jun 1999 11:31

Re: Wuhan Coronavirus Resource Thread

Post by vijayk »

Suraj wrote:^^^ very helpful estimate of future availability .
Wondering why such low number for Nasal vaccine? Why can't we ramp it up? We can administer it easily
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Here is the news story:

Covid: Over 2 bn vaccine doses to be available between Aug-Dec, says Centre
As states grapple with a shortage of coronavirus vaccines, the Centre Thursday said that over two billion doses will be made available in the country in five months between August and December, enough to vaccinate the entire population.

It also said Russian anti-Covid vaccine Sputnik V is likely to be available by next week.

"Two billion doses (216 crore) will be made in the country in five months for India and for people of India. Vaccine will be available for all as we move forward," Niti Ayog Member V K Paul said, adding by the first quarter of the next year, the number is likely to be three billion.

He estimated that between August to December, production of 750 million doses of Covishield is estimated, while 550 million doses of Covaxin will be made available.

Further, Biological E is expected to produce 300 million doses, Zydus Cadila 50 million, Serum Institute of India 200 million doses of Novavax, and Bharat Biotech 100 million doses of its nasal vaccine, while Gennova will make available 60 million doses and Sputnik V 156 million doses.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Suraj-San: This story should make you happy:

Gap between two Covishield doses extended to 12-16 weeks, says govt
Centre on Thursday said it accepted the recommendation of the COVID Working Group for extension of the gap between the first and second doses of Covishield vaccine to 12-16 weeks.

"The COVID Working Group chaired by Dr N K Arora has recommended extension of the gap between the first and second doses of COVISHIELD vaccine to 12-16 weeks from 6-8 weeks. Based on the available real-life evidences, particularly from UK, the COVID-19 Working Group agreed for increasing the dosing interval to 12-16 weeks between two doses of COVISHIELD vaccine. No change in interval of COVAXIN vaccine doses was recommended," said Ministry of Health and Family Welfare on Thursday.

The NTAGI has also stated that those having laboratory test proven SARS-CoV-2 illness should defer COVID-19 vaccination for six months after recovery, sources said, reported PTI.

According to the Union Health Ministry's current protocol, vaccine is to be taken four to eight weeks after recovery from COVID-19 infection and pregnant and lactating women are not to be administered the shots.

"Based on the available real life evidence particularly from the UK, the COVID-19 working group agreed for increasing the dosing interval to 12-16 weeks between two doses of Covishield vaccine.No change in interval of Covaxin vaccine doses was recommended," the sources said.
IndraD
BRF Oldie
Posts: 9305
Joined: 26 Dec 2008 15:38
Location: भारत का निश्चेत गगन

Re: Wuhan Coronavirus Resource Thread

Post by IndraD »

https://timesofindia.indiatimes.com/vac ... 017057.cms
Chinese vaccines' effectiveness low, official admits, aim to do trials by mixing with other vaccines
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Sputnik V vaccine could be available for use in India by next week: Govt
The union government on Thursday said that Russia's Sputnik vaccine will likely be available for use by next week and also the local production of the shot will begin in July.

"Sputnik vaccine has arrived in India. I am happy to say that we are hopeful that it will be available in the market next week. We're hopeful that the sale of the limited supply that has come from there (Russia), will begin next week," said Dr VK Paul, Member (Health) of NITI Aayog.

Addressing a briefing on the vaccination situation in the country, Dr Paul said that the Central government has already procured 350 million vaccine doses for the ongoing vaccination drive and more than 2 billion vaccine doses will be manufactured between August and December.

"Overall, 216 crore doses of vaccines will be manufactured in India between August-December - for India and for Indians. There should be no doubt that vaccine will be available for all as we move forward," he said.

Expressing optimism that more vaccines will be available going forward, Dr Paul said that various arms and departments of government, including the ministry of external affairs (MEA) is in touch with foreign vaccine makers Pfizer, Moderna, Johnson & Johnson.

"They were officially asked if they would like to send doses to or manufacture in India, we will find partners and assist. They had said that they are working in their own way and they would talk of vaccine availability in Q3, in 2021. We are connected to them. I'm hopeful that they will step forward to increase availability in India," he said.

"Any vaccine that is approved by US FDA, WHO can come to India. Import license will be granted within 1-2 days. No import license is pending," Dr Paul further said
.
I read in a story on Yahoo News that India's demand for vaccines, vaccine raw materials, and Covid-related medicines and supplies is so large that it is straining the entire global supply chain. There is no surplus available anywhere in the world right now.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

vijayk wrote:
Suraj wrote:^^^ very helpful estimate of future availability .
Wondering why such low number for Nasal vaccine? Why can't we ramp it up? We can administer it easily
It still has to complete testing and get approval.
Bart S
BRF Oldie
Posts: 2938
Joined: 15 Aug 2016 00:03

Re: Wuhan Coronavirus Resource Thread

Post by Bart S »

Kakkaji wrote:Sputnik V vaccine could be available for use in India by next week: Govt
"Any vaccine that is approved by US FDA, WHO can come to India. Import license will be granted within 1-2 days. No import license is pending," Dr Paul further said[/b].

WHO?!!!

Chinese-controlled WHO has just approved the junk Chinese vaccines. Our Babooze as usual show exceptional skill at shooting the country in the foot.

Oh well, maybe the Chinese vaccines can be allocated to commie ruled states like Kerala and Bengal, Pravin Sahwney, staff of the Hindu, all Magasaysay award winners, anybody at JNU, Pinjra Tod etc.


I read in a story on Yahoo News that India's demand for vaccines, vaccine raw materials, and Covid-related medicines and supplies is so large that it is straining the entire global supply chain. There is no surplus available anywhere in the world right now.
Well, that is a BS and ungrateful spin on it if they are portraying it in that way. For most of these, especially for developing countries and even generics in developed countries India IS the global supply chain. They are happy to keep taking from us and enjoying our low-cost high-quality supplies, but expect that we shouldn't take care of our our own in times of dire crisis.
Last edited by Bart S on 13 May 2021 20:57, edited 1 time in total.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Mixing AstraZeneca and Pfizer shots triggers more fatigue, headaches: Study
Mixing doses of two leading Covid-19 vaccines increased patients’ side effects such as fatigue and headaches in early findings from a study that has yet to show how well such a cocktail defends against the virus.

People who got a first dose of AstraZeneca Plc’s shot followed by Pfizer Inc.’s vaccine four weeks later reported more short-lived side effects, most of them mild, researchers from the University of Oxford reported in The Lancet medical journal. That was also true when the order of the shots was switched.

Mixing doses of two leading Covid-19 vaccines increased patients’ side effects such as fatigue and headaches in early findings from a study that has yet to show how well such a cocktail defends against the virus.

People who got a first dose of AstraZeneca Plc’s shot followed by Pfizer Inc.’s vaccine four weeks later reported more short-lived side effects, most of them mild, researchers from the University of Oxford reported in The Lancet medical journal. That was also true when the order of the shots was switched.
Bart S
BRF Oldie
Posts: 2938
Joined: 15 Aug 2016 00:03

Re: Wuhan Coronavirus Resource Thread

Post by Bart S »

Don't the side effects from vaccines simply mean that the vaccines are triggering a good immune response and hence doing their job? Not necessarily a bad thing, though the results of the efficacy studies are what really is important.
vijayk
BRF Oldie
Posts: 8760
Joined: 22 Jun 1999 11:31

Re: Wuhan Coronavirus Resource Thread

Post by vijayk »

Kakkaji wrote:
vijayk wrote:
Wondering why such low number for Nasal vaccine? Why can't we ramp it up? We can administer it easily
It still has to complete testing and get approval.
I know but Govt. should invest early and keep it ready ... Don't wait for it to be approved.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

PM Modi to interact with DMs of 100 high Covid-19 caseload districts
Prime Minister Narendra Modi will interact with district magistrates of 100 districts with high caseloads of COVID-19 infections in two meetings on May 18 and 20, government sources said on Thursday.

While DMs of 46 districts from nine states will be part of the first meeting, those from 54 districts from 10 states will attend the second meeting, they said, adding that respective chief ministers will be present in these interactions.

This will be the first such interaction that the prime minister will have with top district-level administrative officers on the COVID-19 situation.

So far, he has held a number of meetings with chief ministers from across the country and also, in some cases, from high caseload states on the pandemic situation since its first outbreak in 2020.
Bart S
BRF Oldie
Posts: 2938
Joined: 15 Aug 2016 00:03

Re: Wuhan Coronavirus Resource Thread

Post by Bart S »

vijayk wrote:
Suraj wrote:^^^ very helpful estimate of future availability .
Wondering why such low number for Nasal vaccine? Why can't we ramp it up? We can administer it easily
Probably to do with BB's process for making the vaccines which rely on actual virus that has been inactivated, something that is difficult to mass produce as easily as some of the newer techniques like mRNA.

It's easy to say 'ramp up' but its a lot harder to do. For one it takes money to build BSL3 facilities. Second, it takes time, those facilities don't come up overnight. Thirdly, even if unlimited supplies of money, land, buildings, regulatory approvals etc are available, it takes skilled people to build and staff these production lines and this is the biggest bottleneck.
Last edited by Bart S on 13 May 2021 21:07, edited 1 time in total.
Amber G.
BRF Oldie
Posts: 9263
Joined: 17 Dec 2002 12:31
Location: Ohio, USA

Re: Wuhan Coronavirus Resource Thread

Post by Amber G. »

nandakumar wrote:
Amber G. wrote:From this arXiv: Vaccinated individuals can be infected with B.1.617, but without severe disease. The data go some way to explaining the dominance of this variant in a partially immune population, but highlight that vaccination is still protective for the majority of people.
https://www.biorxiv.org/content/10.1101 ... 8.443253v1
>>> First molecular insights into B.1.617 VOC by collaboration of INSACOG and Gupta Lab.
Only moderate antibody resistance but greater syncytium formation. Overall fits higher transmissibility, ?symptoms, but low severity in vaccinated.
I am hearing stories from people in the friends circle and extended family that they contracted Covid infections despite having had two shots of vaccine. Granted that vaccination is not proof against infection the interesting thing is such instances have come predominantly from those who have had Covishield. This was confirmed by a doctor relative of mine. I wonder if there are exhaustive data on infection among vaccinated individuals and the distribution between the two vaccines currently available.
Don't know about "exhaustive" part ( :) ) but of course there is lot of data which is being studied (and unfortunately people are putting "spin" and sometimes outright silly "analysis" in media). From what I have seen the data / or analysis by people who I respect the bottom line is Vaccines are extremely effective specially for saving a trip to hospital or death. The data (for academic purpose) for different vaccines may be "interesting" but it is clear that both in USA and India - *all* vaccines have been very effective. My take (from the verified data and analysis) :

- If you have taken only one shot and two weeks have passed - Probability for testing positive (or showing symptoms) is about 50% lower.
(Pfizer and Moderna numbers may be a little higher but practically irrelevant)
- Two/three weeks after the all doses ( 65- 95%) less probability that you will catch a virus vs non-vaccinated individual.
(Again - we are comparing oranges with oranges - *vaccine* is *not* the only factor - sometimes ignored in anecdotal evidences - A person with vaccine may be in higher probability if he is out without a mask or his immune system is compromised, or run into B117 type virus in comparison to a healthy person who is in quarantine )

What is encouraging is the morbidity (or serious illness) data - among fully vaccinated individuals (Both here in USA or in India) it is very small (deaths verified due to infection only) - Numbers I have seen is something like (.02% for morbidity and single digit for serious illness). Fortunately this is true also for variants which are in India/USA.

This is true for all the vaccines (Covidshield, Covaxin, Pfizer, Moderna, J&J) -- More data for some, little less data/confidence for others but bottom line they are extremely encouraging.

(Disclaimer - The above is my take based upon what I have read - take it for what ever it's worth)
Last edited by Amber G. on 13 May 2021 21:17, edited 1 time in total.
IndraD
BRF Oldie
Posts: 9305
Joined: 26 Dec 2008 15:38
Location: भारत का निश्चेत गगन

Re: Wuhan Coronavirus Resource Thread

Post by IndraD »

https://www.bloomberg.com/news/articles ... -the-world
Indonesia has good words for Chinese vaccine in new study however it still hasn’t published any data in an academic journal, the gold standard experts use to assess a vaccine
sivab
BRFite
Posts: 1075
Joined: 22 Feb 2006 07:56

Re: Wuhan Coronavirus Resource Thread

Post by sivab »

Image

Official vaccine availability for May: 7.3Crs. Translates to ~2.35 million per day which lines up with daily reported rate.
Kakkaji
BRF Oldie
Posts: 3866
Joined: 23 Oct 2002 11:31

Re: Wuhan Coronavirus Resource Thread

Post by Kakkaji »

Defer vaccination for 6 months after recovery from Covid: Govt panel
A government panel has recommended increasing the gap between two doses of Covishield COVID-19 vaccine to 12-16 weeks, official sources said on Thursday.

No change has been suggested for dosage interval of Covaxin by the National Technical Advisory Group on Immunisation (NTAGI).

It has also suggested that pregnant women may be offered the choice to take any COVID-19 vaccine and that lactating women can be inoculated any time after delivery.

The NTAGI has also stated that those having laboratory test proven SARS-CoV-2 illness should defer COVID-19 vaccination for six months after recovery, the sources said.


According to the current protocol, vaccine must be taken four to eight weeks after recovery from COVID-19 infection.

"Based on the available real life evidence particularly from the UK, the COVID-19 working group agreed for increasing the dosing interval to 12-16 weeks between two doses of Covishield vaccine.No change in interval of Covaxin vaccine doses was recommended," the sources said.
Post Reply